AbbVie Inc (ABBV)vsArriVent BioPharma, Inc. Common Stock (AVBP)
ABBV
AbbVie Inc
$208.84
-2.86%
HEALTHCARE · Cap: $380.25B
AVBP
ArriVent BioPharma, Inc. Common Stock
$24.89
+2.77%
HEALTHCARE · Cap: $1.10B
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AVBP
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1201.2%
Fair Value
$16.05
Current Price
$208.84
$192.79 premium
Intrinsic value data unavailable for AVBP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 91.1x leaves little room for execution misses.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AVBP carries more volatility with a beta of 1.00 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. is a specialized biopharmaceutical company committed to advancing innovative therapies aimed at addressing unmet medical needs in oncology and autoimmune disorders. Leveraging proprietary technologies and a solid scientific foundation, the company is developing a diverse pipeline of potential treatment candidates designed to significantly improve patient outcomes. With a strategic emphasis on high-growth sectors within the biopharma industry, ArriVent presents a compelling investment opportunity for institutional investors seeking exposure to transformative healthcare advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?